Hosted on MSN2mon
New Hope for Metastatic Colorectal Cancer Patients: A Targeted Approach With a Drug Called Encorafenib Gets FDA ApprovalOne particular type of BRAF mutation, called BRAF V600E, is present in around 5% to 10% of patients with metastatic colorectal cancer. Historically, metastatic colorectal cancer driven by a BRAF ...
Braftovi is a small molecule inhibitor of proteins with the BRAF V600E mutation, which can lead to activation of signaling pathways that drive certain cancers, including colorectal cancer.
Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6. Dr. Marwan G. Fakih discussed the FDA approval of ...
Synchronous metastases did not affect survival in resected BRAF V600E-mutated metastatic colorectal cancer. BRAF V600E-mutant metastatic colorectal cancer (CRC) was associated with poor clinical ...
In this video, Arvind N. Dasari, MD, MS, discussed the phase 3 results from the BREAKWATER trial presented at ASCO Gastrointestinal Cancers Symposium.
as well as an increase in overall survival (OS), when used as a first-line treatment for colorectal cancer with BRAF V600E mutations. Both results were "clinically meaningful," according to a ...
Pfizer's Phase 3 BREAKWATER trial showed Braftovi combo significantly improved PFS and OS in colorectal cancer with BRAF V600E mutation. The regimen demonstrated a 60.9% confirmed ORR ...
The Braftovi combination regimen received accelerated approval by the FDA in December 2024 for treatment-naive patients with BRAF V600E-mutant mCRC based on a clinically meaningful and ...
Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has ... the combination in mCRC patients living with a BRAF V600E mutation who are treatment-naive. The top-line data also ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results